Hey there, web surfer!

To search and monitor rising trends,
create an account here. It's free.

Join Treendly

live demand report in US

Astrazeneca Stock Price

Finance    High opportunity   

  

Track this trend
(Monitor this trend over time)

6.6K
searches/mo

 12 Months
Average: 19.37%
Trend: declining
MOM change: -0.51%
 5 Years
Average: 6.05%
Trend: growing
MOM change: 1.68%

Latest forum discussions

We tracked 30 total in the last 3 months

... Busts Presents Opportunity; High-yielding stock offers a haven in the.... The upshot is that the stock is one of the cheapest .... The drug was upstaged by AstraZeneca and Daiichi Sankyo's Enhertu. ... by sticking around. Gilead's stock price is down 7.8% to $... not come with an enormous price tag.''
Published on 2022-06-14 in the GILD forum
This discussion is in English.
....com/article/4510177-novavax-stock-buy-sell-hold-recent-earningsIs... Novavax Stock A Buy, Sell, Or... Comirnaty, Moderna's Spikevax or AstraZeneca's (AZN) Vaxzevira), and...vaccine; Moderna (USA) RNA vaccine; AstraZeneca /Uni Oxford (UK) viral vector...about Novavax share price appreciation. The NVAX share price is down ... one buy. Novavax share price continued to slide over the...
Published on 2022-05-11 in the NVAX forum
This discussion is in English.
....com/article/4510177-novavax-stock-buy-sell-hold-recent-earningsIs... Novavax Stock A Buy, Sell, Or... Comirnaty, Moderna's Spikevax or AstraZeneca's (AZN) Vaxzevira), and...vaccine; Moderna (USA) RNA vaccine; AstraZeneca /Uni Oxford (UK) viral vector...about Novavax share price appreciation. The NVAX share price is down ... one buy. Novavax share price continued to slide over the...
Published on 2022-05-11 in the NVAX forum
This discussion is in English.
...Sciences Corporation office exterior. EXAS stock. Source: Tada Images / Shutterstock 52...being developed in partnership with AstraZeneca (NASDAQ:AZN). It was found ...2022, IONS stock has appreciated 13.8%. At current prices, its price-to-sales...in 2022, TRMB stock has declined 22%. At current prices, forward price-to-earnings and... price-to-sales numbers are 23...
Published on 2022-06-12 in the IONS forum
This discussion is in English.
...Sciences Corporation office exterior. EXAS stock. Source: Tada Images / Shutterstock 52...being developed in partnership with AstraZeneca (NASDAQ:AZN). It was found ...2022, IONS stock has appreciated 13.8%. At current prices, its price-to-sales...in 2022, TRMB stock has declined 22%. At current prices, forward price-to-earnings and... price-to-sales numbers are 23...
Published on 2022-06-12 in the IONS forum
This discussion is in English.
... scrutiny. The CDMO's stock price has tumbled as a result, ... million worth of Emergent stock in January and early February, ... over the facility and AstraZeneca, which was also making its ...Emergent's current market price, they would fetch about $5....of the company�s stock since 2016. The sales were ...to sell at market price. The executive's remaining stake ...more-than-10-million-stock-before-j-j-doses-were-...
Published on 2022-05-10 in the Latest Breaking News forum
This discussion is in English.
... scrutiny. The CDMO's stock price has tumbled as a result, ... million worth of Emergent stock in January and early February, ... over the facility and AstraZeneca, which was also making its ...Emergent's current market price, they would fetch about $5....of the company�s stock since 2016. The sales were ...to sell at market price. The executive's remaining stake ...more-than-10-million-stock-before-j-j-doses-were-...
Published on 2022-05-10 in the Latest Breaking News forum
This discussion is in English.
.... The upshot is that the stock is one of the cheapest .... The drug was upstaged by AstraZeneca and Daiichi Sankyo ’s Enhertu. ... by sticking around. Gilead’s stock price is down 9.9% to $... not come with an enormous price tag.’’ Investors should cheer that ...
Published on 2022-06-15 in the TCRT-PGEN Fundamental & Technical Discussion Board forum
This discussion is in English.
.... The upshot is that the stock is one of the cheapest .... The drug was upstaged by AstraZeneca and Daiichi Sankyo ’s Enhertu. ... by sticking around. Gilead’s stock price is down 9.9% to $... not come with an enormous price tag.’’ Investors should cheer that ...
Published on 2022-06-15 in the TCRT-PGEN Fundamental & Technical Discussion Board forum
This discussion is in English.
... its Aduhelm program, and a stock price down 34.5% over the ... when it was acquired by AstraZeneca (AZN) for $39 billion, and ... be a catalyst for the stock. Abrahams said he doesn't ...
Published on 2022-05-26 in the BIIB forum
This discussion is in English.
... its Aduhelm program, and a stock price down 34.5% over the ... when it was acquired by AstraZeneca (AZN) for $39 billion, and ... be a catalyst for the stock. Abrahams said he doesn't ...
Published on 2022-05-26 in the BIIB forum
This discussion is in English.
INO has no reason to rise. 1) it's overvalued at $450,000,000 for nothing but hype, 2) the Reveal 3100 trial failed, 3) the Omicron trial failed, 4) the Innovate trial was shut down, 5) AstraZeneca terminated a partnership, 6) a reverse split is imminent, 7) the death spiral financing for $300,000,000 will continue to pound the stock price lower.
Published on 2022-07-03 in the Inovio Pharmaceuticals, Inc. (INO) forum
This discussion is in English.
INO has no reason to rise. 1) it's overvalued at $450,000,000 for nothing but hype, 2) the Reveal 3100 trial failed, 3) the Omicron trial failed, 4) the Innovate trial was shut down, 5) AstraZeneca terminated a partnership, 6) a reverse split is imminent, 7) the death spiral financing for $300,000,000 will continue to pound the stock price lower.
Published on 2022-07-03 in the Inovio Pharmaceuticals, Inc. (INO) forum
This discussion is in English.
Novavax needs to do the right thing and sell the company asap. The current management team is way over their head right now. The current stock price and market cap reflects zero confidence in management abilities. We may not get what we had hoped for, but I think $150-$200 is doable. With proper management, JnJ or AstraZeneca could make a fortune with the Novavax product pipeline.
Published on 2022-05-23 in the Novavax, Inc. (NVAX) forum
This discussion is in English.
Novavax needs to do the right thing and sell the company asap. The current management team is way over their head right now. The current stock price and market cap reflects zero confidence in management abilities. We may not get what we had hoped for, but I think $150-$200 is doable. With proper management, JnJ or AstraZeneca could make a fortune with the Novavax product pipeline.
Published on 2022-05-23 in the Novavax, Inc. (NVAX) forum
This discussion is in English.
INO will continue to sink to new lows. 1) it's overvalued at $500,000,000 for nothing but hype, 2) the Reveal 3100 trial failed, 3) the Omicron trial failed, 4) the Innovate trial was shut down, 5) AstraZeneca terminated a partnership, 6) a reverse split is imminent, 7) the death spiral financing for $300,000,000 will continue to pound the stock price lower.
Published on 2022-07-06 in the Inovio Pharmaceuticals, Inc. (INO) forum
This discussion is in English.
INO will continue to sink to new lows. 1) it's overvalued at $500,000,000 for nothing but hype, 2) the Reveal 3100 trial failed, 3) the Omicron trial failed, 4) the Innovate trial was shut down, 5) AstraZeneca terminated a partnership, 6) a reverse split is imminent, 7) the death spiral financing for $300,000,000 will continue to pound the stock price lower.
Published on 2022-07-06 in the Inovio Pharmaceuticals, Inc. (INO) forum
This discussion is in English.
...human placentas. Still, the price on the drug blew minds ...for less money. The price hardly budged.Termeer’s ...Gaucher drug’s price and sticking to it reshaped ...fundamentally broken that the price doesn’t have to ...month, the median list price of a drug first marketed .... Some, like Pfizer and AstraZeneca, list rare diseases.At the ... likely to climb. The stock is trading at a valuation ...
Published on 2022-07-08 in the Biotech forum
This discussion is in English.
...human placentas. Still, the price on the drug blew minds ...for less money. The price hardly budged.Termeer’s ...Gaucher drug’s price and sticking to it reshaped ...fundamentally broken that the price doesn’t have to ...month, the median list price of a drug first marketed .... Some, like Pfizer and AstraZeneca, list rare diseases.At the ... likely to climb. The stock is trading at a valuation ...
Published on 2022-07-08 in the Biotech forum
This discussion is in English.